Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
about
Clinical implications of interferon-γ genetic and epigenetic variantsPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosisPosaconazole liquid suspension in solid organ transplant recipients previously treated with voriconazoleEvaluation of a recombinant antigen-based enzyme immunoassay for the diagnosis of noninvasive aspergillosis.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trialLong-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis.Iatrogenic Cushing's syndrome induced by posaconazole.Late post-operative Aspergillus flavus endocarditis: Demonstration of a six years incubation period using microsatellite typingInterleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon productionAspergillus lung disease in patients with sarcoidosis: a case series and review of the literature.Posaconazole: when and how? The clinician's view.Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.Multifocal pulmonary aspergillomas: case series and review.Safety of posaconazole.Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature.Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.Chronic pulmonary aspergillosis.Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series.Antibody testing in aspergillosis--quo vadis?Republished: The clinical spectrum of pulmonary aspergillosis.Challenges in the management of chronic pulmonary aspergillosis.Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis.Usefulness of Two Aspergillus PCR Assays and Aspergillus Galactomannan and β-d-Glucan Testing of Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis.Posaconazole in lung transplant recipients: use, tolerability, and efficacy.Early or late IL-10 blockade enhances Th1 and Th17 effector responses and promotes fungal clearance in mice with cryptococcal lung infectionA reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluidEpidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis.Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis.Assessment of the significance of respiratory culture of Aspergillus in the non-neutropenic patient. A critique of published diagnostic criteria.The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach.Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention.[Aspergillus in airway material : Ignore or treat?]Environmental fungicides and triazole resistance in Aspergillus.Chronic fibrosing pulmonary aspergillosis: a cause of 'destroyed lung' syndrome.Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis.Major variations inAspergillus fumigatusarising within aspergillomas in chronic pulmonary aspergillosis
P2860
Q28383437-1EA5E2E0-FB36-458F-B7BE-B3EE01B87351Q34532546-9A2D9D20-5BCA-4A8A-B4AE-2F637E661D2FQ35076940-8B3DEF9F-8D74-420F-B4CC-D8A0EA9057F4Q35679674-B3909D19-DFBE-465B-A77E-092A715A9CF9Q35732778-569054C2-DB47-4BDC-B11B-4973A8C68068Q35806908-5BB2E29C-ED55-4932-9B89-7222C62E09F1Q36018743-58EA3FD2-8628-479F-908F-8D116D749262Q36342188-73C659C4-99D3-4D85-A641-35A11FDE518CQ37111641-2511B78A-DEFB-4F54-A81B-ECF4C19B09FAQ37263334-A502802E-3C50-49EF-A231-A419F4960198Q37371998-448E6B4B-2128-44B3-AB16-C722879B8D6DQ37643828-178A17CE-D574-427F-8BC9-E5B3E6B24049Q37843814-A1C13D54-14DB-41DE-A16C-0012E18C8C8CQ37901534-FE4089FC-E493-4260-B1AB-0B5ECE1C0A27Q37989562-5F10AE97-B5DB-40A2-8DDD-3EE3AF192DF7Q38066618-11EBFC48-CB6E-483D-8118-F6E039621255Q38077591-975E3225-EF2B-4389-B558-3454C3540C1FQ38089925-402CE2D3-9F8C-4471-897F-12AABF19F7F4Q38103889-9AAE9037-F145-4D52-82CA-D7A75980FF14Q38168300-6C006BF7-647C-4400-B0B8-91F93761E162Q38272463-18722FEF-E4F3-4D34-A375-A0949D160FAAQ38484090-9C7A95F7-023E-462D-B4DF-7B03C59049D1Q38549796-FCEAEB5C-F28D-48F0-895E-A428891CF76DQ39028585-7F4AE882-5CB5-46C3-9CCC-47FBC28C5177Q40111798-6A4C1AC6-3167-409F-8ADF-B2F96015D3F7Q40283067-2D060D5A-43CB-453A-8512-BD59805E0B07Q40827808-608070E9-CEFE-49E7-A855-E8A1903C0833Q41737626-BB95F13A-3697-4652-8BE2-0BD17F444DE2Q41907424-83661F8D-BE36-4B9E-B977-6C68E2137B0EQ42151667-94252E98-40A4-4645-A22F-43049DB57B81Q43998704-3DBC9252-AB73-42E6-A49B-D2AB3ABF87D2Q44420540-B0C5A341-9F45-42AE-A613-5669B5E53657Q47130266-D2A4FB9E-6549-4C4B-BB68-9268C9344A08Q47645128-9342E363-F01F-4B3F-99EB-853DFFA24BE9Q47715355-581DEDDF-1199-477C-9F86-151AFEEF0CEEQ49546197-8D5A2132-00A4-4E08-933B-CF1D2B1C15D8Q51042801-C657EE95-2D01-4213-8F8C-B535D76A9F98Q52971199-5CE1603F-49C8-4099-B210-D3BE681F3DF8Q53696861-553DE2BA-63AE-47D8-B605-86CF33204B7FQ56837233-6A299E6E-59E0-4B3E-810F-F372E8E56B4C
P2860
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
@en
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
@nl
type
label
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
@en
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
@nl
prefLabel
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
@en
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
@nl
P2093
P50
P356
P1476
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
@en
P2093
Caroline B Moore
Caroline Baxter
Timothy W Felton
P304
P356
10.1086/657306
P407
P577
2010-11-05T00:00:00Z